Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally

David J Lewis, Carol A Fraser, Abdel N Mahmoud, Rebecca C Wiggins, Maria Woodrow, Alethea Cope, Chun Cai, Rafaela Giemza, Simon A Jeffs, Maria Manoussaka, Tom Cole, Martin P Cranage, Robin J Shattock, Charles J Lacey

Research output: Contribution to journalArticlepeer-review


We conducted a phase 1 double-blind randomised controlled trial (RCT) of a HIV-1 envelope protein (CN54 gp140) candidate vaccine delivered vaginally to assess immunogenicity and safety. It was hypothesised that repeated delivery of gp140 may facilitate antigen uptake and presentation at this mucosal surface. Twenty two healthy female volunteers aged 18-45 years were entered into the trial, the first receiving open-label active product. Subsequently, 16 women were randomised to receive 9 doses of 100 µg of gp140 in 3 ml of a Carbopol 974P based gel, 5 were randomised to placebo solution in the same gel, delivered vaginally via an applicator. Participants delivered the vaccine three times a week over three weeks during one menstrual cycle, and were followed up for two further months. There were no serious adverse events, and the vaccine was well tolerated. No sustained systemic or local IgG, IgA, or T cell responses to the gp140 were detected following vaginal immunisations. Repeated vaginal immunisation with a HIV-1 envelope protein alone formulated in Carbopol gel was safe, but did not induce local or systemic immune responses in healthy women. TRIAL REGISTRATION: NCT00637962.
Original languageEnglish
Article numbere25165
Pages (from-to)e25165
JournalPLoS ONE
Issue number9
Publication statusPublished - 30 Sept 2011

Cite this